ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Navigating an Ever Evolving Regulatory and Pharmacovigilance Landscape
Chuhua Wu outlines the variations in the structures, processes and outcomes of pharmacovigilance status among Asian countries.
Risk-Based Monitoring and Real-World Data: A Decentralised Ecosystem
Ian O'Shaughnessy considers how to ensure a reality for the bright future of digitisation as clinical trials evolve.
A Strategic Business Plan to ensure success under MDR/IVDR
David Novotny and Angela Brown outline how manufacturers can develop a strategic business model that will prepare them for success under new MDR/IVDR reforms.
Using Clinical Decision Support Tools To Facilitate Decision-Making In Precision Medicine
This article featured in Forbes considers how technology – particularly AI and big data – can enable precision medicine.
Trends in Biosimilar Market Access
A thought leadership article authored by Jenny Lee and Gene Chieh, investigating how biosimilars have gained momentum in a growing number of markets.
Biomarker-driven Landscape in Clinical Trials
An interview with Nicole Cowan covering the new biomarker-driven landscape in clinical trials and the nuances of drug-diagnostics co-development programs.
Social Media Outreach
ICON expert Gretchen Goller considers social media outreach's beneficial effect on patient connectivity to date in the October 2019 edition of PharmaVoice.
Making it Easier for the Site to Succeed
A thought leadership article authored by EB McLindon, discussing how making clinical research easier for the site can also make life easier for sponsors.
ICON to Offer At-Home Clinical Trials following Symphony Purchase
ICON boosts its hybrid clinical trial and site support services with the acquisition of Symphony Clinical Research, a provider of in-home and alternate site services.
Alzheimer’s in Clinical Trials – Is There a Way Out of Ongoing Failures?
A thought leadership article authored by Peter Scheuler, exploring how the series of failures in Alzheimer’s disease research has provided insights into the disease pathology, study methodologies and - as a consequence – in the design of future development programmes for anti-Alzheimer medications.